Impact of the Use of Cox-2 Inhibitors on Bone Mass of Menopause Women

Pharmacologically non-steroidal anti-inflammatory drugs have the main target of the cyclooxygenase (COX) enzyme as a good pain therapy in patients with chronic inflammation such as osteoarthritis and Rheumatic arthritis. COX-2 can be induced by cytokines, growth factors, and other stimuli based on the inflammatory response. There is an increase in the consumption of non-steroidal anti-inflammatory drugs in postmenopausal women. The purpose of this study was to determine the impact of using COX-2 inhibitors on bone mass in postmenopausal women. The study used an analytical observational research technique with a cross sectional design. The sample was carried out by purposive sampling on 33 postmenopausal women who taking COX-2 inhibitors for more than 6 months and 33 postmenopausal women who did not take COX-2 inhibitors.The research instrument measures bone mineral density using the technique Dual energy X-ray Absorptiometry (DXA) or tool Bone Mineral Density (BMD) Sonography namely OsteoSysSonost 3000. The Mann-Whitney test showed that the value of p = 0.000 <0.05, there was significant difference in the BMD (Bone Mineral Density) measure between postmenopausal women using COX-2 Inhibitors and menopausal women not using COX-2 Inhibitors. There is an effect of the use of COX-2 Inhibitors on bone mass in postmenopausal women. On average, the Bone Mineral Density Sonography of postmenopausal women using COX-2 Inhibitors was significantly lower, compared to postmenopausal women without COX-2 Inhibitors. It is necessary to supervise postmenopausal women regarding the long-term use of COX-2 inhibitors.